Home » Stocks » Phio Pharmaceuticals

Phio Pharmaceuticals Corp. (PHIO)

Stock Price: $2.12 USD -0.04 (-1.85%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed
After-hours: $2.10 -0.02 (-0.94%) Oct 23, 7:34 PM

Stock Price Chart

Key Info

Market Cap 12.25M
Revenue (ttm) n/a
Net Income (ttm) -8.78M
Shares Out 5.78M
EPS (ttm) -4.51
PE Ratio n/a
Forward PE 0.81
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $2.12
Previous Close $2.16
Change ($) -0.04
Change (%) -1.85%
Day's Open 2.23
Day's Range 2.10 - 2.23
Day's Volume 78,638
52-Week Range 1.60 - 18.15

More Stats

Market Cap 12.25M
Enterprise Value n/a
Earnings Date (est) Nov 11, 2020
Ex-Dividend Date n/a
Shares Outstanding 5.78M
Float 5.76M
EPS (basic) -10.55
EPS (diluted) -4.51
FCF / Share -1.77
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 11,926
Short Ratio 0.03
Short % of Float 0.21%
Beta 2.32
PE Ratio n/a
Forward PE 0.81
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 0.70
Revenue n/a
Operating Income -8.81M
Net Income -8.78M
Free Cash Flow -8.81M
Net Cash 18.22M
Net Cash / Share 3.15
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -34.06%
ROE -63.97%
ROIC 4,106.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (1)

Buy 1
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$6.50*
(206.60% upside)
Low
4.00
Current: $2.12
High
9.00
Target: 6.50
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015201420132012
Revenue0.020.140.020.020.030.070.400.10
Revenue Growth-84.78%820%-21.05%-44.12%-52.11%-82.21%311.34%-
Gross Profit0.020.140.020.020.030.070.400.10
Operating Income-8.99-7.36-14.06-9.02-10.24-8.83-20.95-12.98
Net Income-8.91-7.36-12.45-8.99-10.22-8.80-20.93-12.88
Shares Outstanding0.460.130.040.010.01---
Earnings Per Share-19.33-57.46-303.63-902.64-1,155.12-4,345.44-15,841.58-30,913.09
Operating Cash Flow-8.65-7.52-9.51-7.76-7.32-7.76-6.31-5.06
Capital Expenditures-0.07-0.01-0.20--0.06-0.08-0.080.02
Free Cash Flow-8.72-7.53-9.72-7.76-7.37-7.84-6.39-5.04
Cash & Equivalents6.9814.933.6312.9610.678.5514.445.18
Total Debt0.52------0.01
Net Cash / Debt6.4714.933.6312.9610.678.5514.445.18
Assets8.0415.324.1013.4011.169.1914.945.59
Liabilities2.291.742.272.542.276.4410.001.71
Book Value5.7513.581.8310.868.892.754.94-5.84
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Phio Pharmaceuticals Corp.
Country United States
Employees 11
CEO Gerrit Dispersyn

Stock Information

Ticker Symbol PHIO
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: PHIO

Description

Phio Pharmaceuticals, a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer in the United States. The company's lead product candidate is RXI-109, an sd-rxRNA that reduces the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin and eye. The company also develops Samcyprone, a topical formulation of the small molecule diphenylcyclopropenone for the clearance of common warts; and RXI-231, an sd-rxRNA compound targeting tyrosinase for use as a cosmetic ingredient that enhances the appearance of uneven skin tone and pigmentation. In addition, it develops RXI-109 that reduces the progression of retinal scarring. The company has collaborations with the Gustave Roussy and Medigene AG, as well as with Helmholtz Zentrum München. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.